Abstract: Surgery in combination with chemotherapy and radiotherapy is the standard of lung cancer treatment, but postoperative recurrence is very common which usually leads to higher mortality and lower life quality. Immunotherapy on postoperative patients fully mobilizes the body′s defense mechanisms, activates the immune cells, and kills residual cancer cells. Current research on lung cancer immunotherapy mainly includes four categories: adoptive immunotherapy, dendritic cell vaccine, nonspecific antigen immune therapy and antigenspecific vaccine.These studies show lung cancer immunotherapy intervention can effectively reduce postoperative residual cancer cells, reduce postoperative recurrence rate, prolong survival, significantly improve the prognosis, and is worth spreading in clinical practice.

Key words: Immunotherapy, Lung neoplasms, Clinical trial